RejuvaKnee (meniscus implant)

2024: Product Announcement

In mid-October 2024, Regenity Biosciences received approval to sell a RejuvaKnee implant to treat soft tissue injuries and the meniscus of the knee. Minimally invasive collagen-meniscus implant promotes meniscus strengthening and repair in case of its injuries. According to the developers, RejuvaKnee provides more complete recovery, promoting the regeneration of its own meniscus tissue, as opposed to standard surgery with replacement of damaged tissues. It is known that meniscectomy can provide high short-term rates of clinical success, but often results in repeated meniscectomy or predisposes to osteoarthritis, unlike RejuvaKnee, which extends the life of the injured knee.

RejuvaKnee™ is a natural bovine collagen implant that facilitates host tissue ingrowth and repair of damaged or injured meniscus tissue. In human corpse research, Regenity partnered with a group of leading sports medicine professionals to demonstrate the simplicity of arthroscopic implantation using a wide range of tools currently available on the market.

𝓲

Massdevice

In a 12-month animal study using RejuvaKnee, it was shown that after three months, the regenerated meniscus could withstand the load of the animal's total weight. In addition, the knee returned to its normal range of motion. The company claims that the results of these studies are significantly superior to the results of traditional meniscectomy and allotransplantation. Regenity researchers also note that during the assessment of neovascularization and histological examination, they obtained data on healthy tissue regeneration against the background of the use of the RejuvaKnee implant, which accelerates soft tissue recovery by five times and is then absorbed by normal tissues.^[1]

Notes